이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Valerio Therapeutics Société anonyme 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Shefali Agarwal

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	3yrs
CEO 소유권	n/a
경영진 평균 재임 기간	1.3yrs
이사회 평균 재임 기간	3.2yrs

최근 관리 업데이트

How Much Did Onxeo's (EPA:ALONX) CEO Pocket Last Year?

Dec 21

Recent updates

CEO

Shefali Agarwal (51 yo)

3yrs

테뉴어

Dr. Shefali Agarwal, M.D., M.P.H is President, CEO & Chairwoman of Valerio Therapeutics Société anonyme from April 07, 2022. Dr. Agarwal was Independent Director & President of Valerio Therapeutics Société...

리더십 팀

이름	위치	테뉴어	보상	소유권
Shefali Agarwal	President	3yrs	데이터 없음	데이터 없음
Joyce Carey	Executive Director of Finance and Head of FP&A	1.3yrs	데이터 없음	데이터 없음
Robin Sutherland	VP & Global Head of Human Resources	1.5yrs	데이터 없음	데이터 없음
Michel Forest	Chief Pharmacist & Quality Assurance Director	no data	데이터 없음	데이터 없음
Huiping Jiang	Senior Vice President of Regulatory Affairs & Quality Assurance	1.8yrs	데이터 없음	데이터 없음
Wael Jdey	Head of Preclinical	1.3yrs	데이터 없음	데이터 없음
Donna Cabral-Lilly	VP & Head of CMC	1.3yrs	데이터 없음	데이터 없음
Pam Slatcher	Head of Global PV	1.2yrs	데이터 없음	데이터 없음

1.3yrs

평균 재임 기간

경험이 풍부한 관리: ALVIO 의 관리팀은 경험 (평균 재직 기간 1.3 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Shefali Agarwal	President	3.1yrs	데이터 없음	데이터 없음
Jacques Mallet	Independent Director	2.8yrs	데이터 없음	데이터 없음
Khalil Barrage	Representative Director	2.1yrs	데이터 없음	데이터 없음
Julien Miara	Director	3.8yrs	데이터 없음	데이터 없음
Nicolas Trebouta	Representative Director	13.1yrs	데이터 없음	데이터 없음
Ruth Plummer	Member of Scientific Advisory Committee	3.2yrs	데이터 없음	데이터 없음
Bryan Giraudo	Independent Director	2.7yrs	데이터 없음	데이터 없음
Robert Coleman	Independent Director	2.8yrs	데이터 없음	데이터 없음
Gilbert Chu	Member of Scientific Advisory Committee	3.2yrs	데이터 없음	데이터 없음
Gilles Favre	Member of Scientific Advisory Committee	3.2yrs	데이터 없음	데이터 없음
Lorenzo Galluzzi	Member of Scientific Advisory Committee	3.2yrs	데이터 없음	데이터 없음
Caroline Robert	Member of Scientific Advisory Committee	3.2yrs	데이터 없음	데이터 없음

3.2yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 이사회: ALVIO 의 이사회는 경험(평균 재직 기간 3.1 년)으로 간주됩니다.

Valerio Therapeutics Société anonyme 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Onxeo S.A. Appoints Khalil Barrage as New Board Member

Onxeo SA, Annual General Meeting, Jun 15, 2022

High number of new and inexperienced directors

Onxeo S.A. Announces Executive Changes

How Much Did Onxeo's (EPA:ALONX) CEO Pocket Last Year?

Onxeo SA Announces Board Changes

Recent updates

Valerio Therapeutics S.A. Provides Clinical Development Update on Its Phase 1/2 VIO-01 Clinical Trial

Onxeo SA to Report Fiscal Year 2022 Results on Mar 30, 2023

Onxeo SA Provides Update on the Development Program For Drug Candidate AsiDNATM

Onxeo SA Advances Its Second Lead Candidate Ox425 for the Treatment of Solid Tumors

Onxeo SA Announces the Enrollment of the First Patient in the Phase 1B/2 Clinical Study Conducted by the European Itcc Consortium and Sponsored by Institut Curie

Nasdaq Approves the Delisting of Onxeo's Shares from the First North Growth Market in Copenhagen

Onxeo Ordinary Shares to Be Deleted from OTC Equity

Onxeo SA Announces U.S. Food and Drug Administration Clears Initial IND Drug Candidate AsiDNA

Onxeo S.A. Appoints Khalil Barrage as New Board Member

Onxeo SA, Annual General Meeting, Jun 15, 2022

High number of new and inexperienced directors

Full year 2021 earnings released: €0.07 loss per share (vs €0.015 profit in FY 2020)

Onxeo S.A. Announces Executive Changes

Onxeo SA to Present New Preclinical Data Highlighting Asidna’s Ability to Fight Tumor Resistance and Protect from Anticancer Treatment Toxicity At Aacr Annual Meeting 2022

Onxeo SA to Present New Preclinical Data Highlighting Asidna’s Ability to Fight Tumor Resistance and Protect from Anticancer Treatment Toxicity At Aacr Annual Meeting 2022

Onxeo’s New Preclinical Data Confirm the Relevance of Combining AsiDNA™ With PARP Inhibitors in Treating Homologous Recombination Proficient Tumors

Is Onxeo (EPA:ALONX) Weighed On By Its Debt Load?

First half 2021 earnings released: €0.057 loss per share (vs €0.075 profit in 1H 2020)

Onxeo S.A. Receives Notice of Allowance for New Patent Broadening the Protection of AsiDNA™ in Combination with a PARP Inhibitor in the United States

Onxeo's (EPA:ALONX) Earnings Are Built On Soft Foundations

Full year 2020 earnings released: EPS €0.01 (vs €0.55 loss in FY 2019)

Onxeo (EPA:ALONX) Share Prices Have Dropped 76% In The Last Five Years

Onxeo Enters Clinical Research Agreement with Institut Curie to Conduct a Phase 1b/2 Clinical Trial of AsiDN

Onxeo SA to Report First Half, 2021 Results on Jul 28, 2021

How Much Did Onxeo's (EPA:ALONX) CEO Pocket Last Year?

Onxeo SA's (EPA:ONXEO) Profit Outlook

Analysts update estimates

New 90-day high: €0.71

Onxeo S.A. Announces Completion of Patient Enrollment in DRIIV-1b Study

New 90-day low: €0.60

First half earnings released

New 90-day low: €0.65

First half earnings released

Onxeo SA Announces Board Changes

CEO

테뉴어

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간

평균 연령